SOCIUM

SOCIUM is an innovative research result of the National Institute of Advanced Industrial Science and Technology, founded in 2017 by CEO Katsuhisa HORIMOTO, Ph.D., who previously served as Senior Invited Researcher at AIST. The company focuses on drug discovery for patients with no drug or ineffective drug, aiming to serve unmet medical needs through unique technology. Their core business segments include drug discovery and development, drug discovery consulting, and phosphorylation analysis services.

The company's proprietary technology, 'Phospho-Totum,' is a comprehensive phosphorylation array analysis platform that reproduces signal transduction pathways at the systems level. It uses a glass plate where kinases in cell lysates phosphorylate substrates, which are then detected via fluorescence. The measurement data analysis software outputs phosphorylation substrate groups, kinase activity scores, and pathway activity scores specific to the sample measurement conditions.

SOCIUM provides three main services: drug discovery and development, drug discovery consulting, and phosphorylation analysis services using their original protein arrays. These services help identify target molecules, develop hypotheses on molecular mechanisms of action, and fulfill specific requests for quantitative rankings of On/Off target molecules in a mimic cell environment.

The company's analysis software can generate multifaceted solutions by explaining molecular mechanisms from two perspectives: specific substrates/kinases and the pathways they influence. This multi-layered structure allows them to provide high-precision analysis software features that output substrate groups, kinases, and pathways specific to the measurement conditions.

SOCIUM's phosphorylation analysis service requires a lower limit of protein concentration between 100–200 μg/L and can tolerate cell lysates from non-human species. The entire protein structure is spotted, and detection is possible using cell lysates derived from a variety of samples, including tissue, blood, and cell lines.

To ensure data analysis accuracy, three arrays are used per set of conditions, with data from N=9 (3 sets per array × 3 arrays) being measured. This approach ensures that the results are reliable and accurate for the specific measurement conditions being analyzed.

The company's news highlights include receiving two use patents in August 2026, launching drug discovery consulting services in July 2026, and completing subject enrollment for an investigator-initiated clinical trial of SO-002 in June 2026. These recent developments demonstrate their active engagement in research and development.

The company's board includes Makoto MIURA, a Certified Public Accountant who joined in October 2018 and engages in top management consulting. Outside Director Tadashi HORIUCHI, Ph.D., previously worked at Daiichi Sankyo Co., Ltd. and Keio University, bringing significant industry experience to the board.

The company's COO, Hideka OKINA, has a track record of exporting measurement instruments specialized for phosphorylation arrays manufactured by SOCIUM Inc. to China, as well as importing health foods from South Korea, demonstrating their international business reach.

The company's website provides a contact form for inquiries, requiring a brief description, company/organization name, name, email, and agreement to the privacy policy, making it easy for potential clients to reach out.

The official website of SOCIUM is socium.co.jp.

On Trustburn, SOCIUM has a rating of 4.1 out of 5 based on 9 reviews.